Business Context and Reporting Period
This Form 8-K Current Report was filed by Oncocyte Corporation (trading symbol: OCX) on April 13, 2022, with the report date finalized on April 19, 2022. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 26,266,417 shares of Common Stock and 26,266,417 Warrants (each warrant exercisable for 0.5 shares).
- Offering Price: Combined price of $1.3325 per unit ($1.3225 per share + $0.01 per warrant).
- Over-Allotment: Underwriters exercised the option to purchase 3,939,962 additional Warrants on April 14, 2022. The option to purchase additional shares remains open for 30 days.
- Net Proceeds: Approximately $32.9 million (including proceeds from the exercised warrant over-allotment).
- Underwriter: BTIG, LLC.
- Closing Date: April 19, 2022.
Material Changes and Unusual Items
The primary material change is the significant capital raise through the issuance of new equity and warrants. The filing notes that there is no established public trading market for the Warrants, and the Company does not intend to list them on any national securities exchange. The transaction was executed pursuant to an effective shelf registration statement (Form S-3) filed in May 2021.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The primary risk disclosed relates to the lack of a trading market for the issued Warrants. The summary of the transaction is qualified by reference to the full Underwriting Agreement and Form of Warrant filed as exhibits.
Investor Verification Checklist
- Verify the final number of shares issued if the underwriters exercise the remaining over-allotment option for shares within the 30-day period.
- Review the Underwriting Agreement (Exhibit 1.1) for specific underwriting discounts and commissions not detailed in the summary.
- Confirm the dilution impact of the 26,266,417 new shares plus the potential 13,133,208.5 shares from warrant exercises.
- Check subsequent filings for the final closing statement and actual net proceeds received.